Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis[2] that targets IL-20.[3]

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
  3. ^ Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.


Allikas: https://en.wikipedia.org/wiki/Fletikumab
No tags for this post.